Sign up
Pharma Capital

ANGLE ground-breaking liquid biopsy to be used in lung cancer study

The Partsortix system will be used in research being carried out by the Hellenic Oncology Research Group
doctors inspecting lung x-ray
Lung cancer has the highest mortality rate of all cancers and there are 2.1mln new cases each year

ANGLE PLC’s (LON:AGL, OTCQX:ANPCY) ground-breaking liquid biopsy system will be incorporated into a clinical study to provide an early warning of relapse among patients being treated for non-small cell lung cancer.

The Partsortix system will be used in research being carried out by the Hellenic Oncology Research Group and will be deployed to track circulating tumour DNA, fragments of dead cancer cells and circulating tumour cells (CTCs).

A total of 50 operable early-stage patients will have blood drawn prior to surgery, one month after the operation and then every three to six months until relapse. 

CTC evaluation is being undertaken by the University of Athens, lead by Professor Evi Lianidou, and the latest collaboration builds on work by the same team using Parsortix in research on head and neck cancer.

 "This is another example of ANGLE's product based leveraged R&D approach delivering key benefits with a major study, which is being developed, executed and funded by a leading customer,” said ANGLE chief executive Andrew Newland. 

“The high incidence and mortality rates of lung cancer create a pressing need for repeat biopsies to allow personalised medicine and we hope that our Parsortix liquid biopsy system can play a key role in delivering this to the benefit of patients, opening new markets for ANGLE."

Shares in ANGLE held steady at 67p in late afternoon trading on Friday.

 -- Adds share price --

Ian_55ae0ddd437b7.jpg
Why Invest In ANGLE PLC? Read More Here

Register here to be notified of future AGL Company articles
View full AGL profile View Profile
View All

Related Articles

1550850611_CancerHeadline.jpg
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.